Filter
859
Text search:
MDR-TB
Featured
89
230
Language
Document type
638
72
67
21
20
15
14
9
2
1
Countries / Regions
62
47
33
26
19
17
16
14
14
14
13
13
13
12
12
10
9
9
9
9
9
9
8
8
7
7
6
6
5
5
5
5
5
4
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
305
80
25
10
8
7
7
Toolboxes
489
57
33
20
13
10
8
7
7
7
4
4
4
3
2
2
2
2
1
1
1
Anti-tuberculosis drug resistance among tuberculosis patients in Ukraine and risk factors for MDR-TB
Results of the first national survey, 2013–2014
Following the encouraging initial results of the pilot project, the Ministry of Health is committed to increasing access to MDR-TB diagnosis, treatment and care. An expansion plan for the programmat
...
The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for
...
This guide provides practical, step-by-step guidance on how to organize, implement, and monitor community-based care for DR TB. It is equally useful for program planning or supervision. The target audience for this guide is TB Program Managers, governments, policy makers, nongovernmental organizatio
...
Tuberculosis MDR-TB & XDR-TB The 2008 Report
For full course visit: https://drtbnetwork.org/training-course-MDR-TB
This course has been designed to take three days. It is composed of lectures, in-class readings, exercises, case discussions, a
...
This report describes the geographical and temporal distribution of multidrug-resistant (MDR) tuberculosis (TB) using molecular typing data reported by European Union (EU)/European Economic Area (EEA) Member States for 2015 and the preceding years.
Specific measures are being taken within the National Tuberculosis Control Programme (NTP) to address the MDR TB problem through appropriate management of patients and strategies to prevent the prop
...
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months
...
Adapted from a fact sheet on TB from the International Council of Nurse’s Global TB/MDR-TB Resource Centre at: http://www.icn.ch/tb/stigma.htm.
Accessed November 2017
The WHO South-East Asia (SEA) Region bears a high burden of tuberculosis (TB) and MDR-TB. In 2015, the Region accounted for nearly 200 000 or 35% of the global estimated new RR/
...
Rev Panam Salud Publica. 2021;45:e74.
Some characteristics of patients and healthcare providers influence treatment success in MDR-TB cases. Physicians’ and nurses’ knowledge about
...
The 7th edition of the Orange Guide provides practical guidance to health workers on the front line of TB control. It includes sections on HIV, MDR-TB and a review of the recommended treatment regim
...
The third edition, released in 2018, has grown to include a total of 18 chapters, contributed by 20 experts and authors from many countries. The goal remains the same: to educate primary care providers on the best practices in TB diagnosis, treatment and follow-up. All articles are richly illustrate
...
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB,
...
Myanmar is one of the world’s 22 high tuberculosis (TB) burden countries, and supporting TB control in Myanmar is a global priority. This report reflects the findings, discussions, conclusions and recommendations of the fourth international review mission of the Myanmar National TB Programme (NTP)
...
In 2019, an estimated 10 million individuals fell ill with tuberculosis (TB) and 3 million of them were not reported to have beendiagnosed and notified. The gap is proportionately even wider for drug-resistant TB. Of the estimated 465 000 patients with rifampicin-resistant and multi-drug resistant T
...
